Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10142-10143
10.1182/blood-2022-169046